Table 2: Proportion of Women, Patients of Colour and Sex/Race-specific Outcomes in CIED-related Physiologic Parameter Monitoring Studies.

Study	Target Population	Location	Women n (%)	Patients of Colour n (%)	Sex/race-specific Subgroup Analyses for the Primary Outcome (p-value for interaction)
TRUST (2010)[92]	Prior ICD implantation per guidelines	US	368 (27.5)	NR	NR
PARTNERS HF (2010)[36]	Prior CRT-D, EF ≤ 35%, NYHA III–IV, QRS ≥ 130 ms	US	227 (32.7)	102 (14.7)	NR
DOT-HF (2011)[35]	Prior ICD or CRT-D, EF < 35%, NYHA II–IV, last HF hospitalisation within 12 months	Europe, Africa, Middle East, Asia	47 (14.0)	NR	NR
SENSE-HF (2011)[93]	Prior to ICD or CRT-D, the last HF hospitalisation within 12 months	Europe, China, UK	79 (16.0)	NR	NR
ECOST (2013)[32]	Prior ICD implantation per guidelines and NYHA II–III	France	51 (11.8)	NR	Risk of major adverse events in women (HR 0.98; 95%CI [0.45–2.13])
DEFEAT-PE (2014)[31]	Prior ICD or CRT-D with 1 HF-related episode within 6 months	US	42 (29.2)	61 (42.4)	NR
IN-TIME (2014)[34]	Prior ICD or CRT-D, EF < 35%, NYHA II–III	Australia, Europe, Israel	128 (19.2)	NR	Worsening clinical score at 12 months (death, HF hospitalisation, change in clinical status) in women (HR 0.54; 95%CI [0.23–1.17])
LIMIT-CHF (2016)[30]	Prior ICD or CRT-D with previous HF admission, EF < 50%, and NYHA III	UK	5 (6.3)	NR	NR
MultiSENSE (2017)[37]	Prior CRT-D with prior HF event within 12 months, NYHA II–IV within 6 months	US, Europe	273 (28.0)	322 (33.0)	NR

CRT-D = cardiac resynchronisation therapy–defibrillator; EF = ejection fraction; HF = heart failure; NYHA = New York Heart Association.